Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases
| العنوان: | Prognostic effect of HER2 evolution from primary breast cancer to breast cancer metastases |
|---|---|
| المؤلفون: | Sanja, Löb, Eva, Linsmeier, Saskia-Laureen, Herbert, Tanja, Schlaiß, Matthias, Kiesel, Jörg, Wischhusen, Jessica, Salmen, Peter, Kranke, Anne, Quenzer, Florian, Kurz, Claire, Weiss, Elena, Gerhard-Hartmann, Achim, Wöckel, Joachim, Diessner |
| المصدر: | Journal of Cancer Research and Clinical Oncology. |
| بيانات النشر: | Springer Science and Business Media LLC, 2022. |
| سنة النشر: | 2022 |
| مصطلحات موضوعية: | Cancer Research, Oncology, General Medicine |
| الوصف: | Purpose Therapeutic options for breast cancer (BC) treatment are constantly evolving. The Human Epidermal Growth Factor 2 (HER2)-low BC entity is a new subgroup, representing about 55% of all BC patients. New antibody–drug conjugates demonstrated promising results for this BC subgroup. Currently, there is limited information about the conversion of HER2 subtypes between primary tumor and recurrent disease. Methods This retrospective study included women with BC at the University Medical Centre Wuerzburg from 1998 to 2021. Data were retrieved from patients' records. HER2 evolution from primary diagnosis to the first relapse and the development of secondary metastases was investigated. Results In the HR-positive subgroup without HER2 overexpression, HER2-low expression in primary BC was 56.7 vs. 14.6% in the triple-negative subgroup (p p = 0.03). In patients with secondary metastases, HER2-low was 75.6% vs. 50% in the triple negative subgroup (p = 0.10). The subgroup of HER2-positive breast cancer patients numerically increased in the course of disease; the HER2-negative overall cohort decreased. A loss of HER2 expression from primary BC to the first relapse correlated with a better OS (p = 0.018). No clinicopathological or therapeutic features could be identified as potential risk factors for HER2 conversion. Conclusion HER2 expression is rising during the progression of BC disease. In view of upcoming therapeutical options, the re-analysis of newly developed metastasis will become increasingly important. |
| تدمد: | 1432-1335 0171-5216 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32bfb7d25ea1b62fd412795b11d239b7 https://doi.org/10.1007/s00432-022-04486-0 |
| حقوق: | OPEN |
| رقم الأكسشن: | edsair.doi.dedup.....32bfb7d25ea1b62fd412795b11d239b7 |
| قاعدة البيانات: | OpenAIRE |
Find this article in full text from Springer Verlag. | تدمد: | 14321335 01715216 |
|---|